Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Potassium Chloride→

Potassium Chloride Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
7447-40-7
Molecular formula
KCl
Molecular weight
74.551 g/mol
Drug class
Potassium saltelectrolyte replacement agent
Mechanism of action
Dissociates to provide potassium ions required for resting membrane potential, neuromuscular transmission and normal cardiac conduction. Replacement corrects potassium depletion but does not directly treat the underlying cause of hypokalaemia.
Indications / reported uses
  • Prevention and treatment of hypokalaemia in patients who cannot obtain adequate potassium from diet or oral supplements, including oral and intravenous formulations; dose, route and rate depend on serum potassium and renal function

Sources: US DailyMed — Potassium chloride oral and injection products · NHS — Potassium supplements · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Potassium salt; electrolyte replacement agent

Mechanism of action

Dissociates to provide potassium ions required for resting membrane potential, neuromuscular transmission and normal cardiac conduction. Replacement corrects potassium depletion but does not directly treat the underlying cause of hypokalaemia.

General use cases

  • Prevention and treatment of hypokalaemia in patients who cannot obtain adequate potassium from diet or oral supplements, including oral and intravenous formulations; dose, route and rate depend on serum potassium and renal function

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Potassium Chloride Environmental Risk Assessment (ERA) (the Potassium Chloride ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.